These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 18371178)
21. Anti-angiogenic treatment strategies for malignant brain tumors. Kirsch M; Schackert G; Black PM J Neurooncol; 2000; 50(1-2):149-63. PubMed ID: 11245274 [TBL] [Abstract][Full Text] [Related]
22. Essential role of TRPC6 channels in G2/M phase transition and development of human glioma. Ding X; He Z; Zhou K; Cheng J; Yao H; Lu D; Cai R; Jin Y; Dong B; Xu Y; Wang Y J Natl Cancer Inst; 2010 Jul; 102(14):1052-68. PubMed ID: 20554944 [TBL] [Abstract][Full Text] [Related]
23. Human alloreactive CTL interactions with gliomas and with those having upregulated HLA expression from exogenous IFN-gamma or IFN-gamma gene modification. Read SB; Kulprathipanja NV; Gomez GG; Paul DB; Winston KR; Robbins JM; Kruse CA J Interferon Cytokine Res; 2003 Jul; 23(7):379-93. PubMed ID: 14511464 [TBL] [Abstract][Full Text] [Related]
24. Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. Ugur HC; Ramakrishna N; Bello L; Menon LG; Kim SK; Black PM; Carroll RS J Neurooncol; 2007 Jul; 83(3):267-75. PubMed ID: 17310267 [TBL] [Abstract][Full Text] [Related]
25. Evidence that Cereport's ability to increase permeability of rat gliomas is dependent upon extent of tumor growth: implications for treating newly emerging tumor colonies. Bartus RT; Snodgrass P; Dean RL; Kordower JH; Emerich DF Exp Neurol; 2000 Jan; 161(1):234-44. PubMed ID: 10683290 [TBL] [Abstract][Full Text] [Related]
26. Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. Takagi H; Koyama S; Seike H; Oh H; Otani A; Matsumura M; Honda Y Invest Ophthalmol Vis Sci; 2003 Jan; 44(1):393-402. PubMed ID: 12506101 [TBL] [Abstract][Full Text] [Related]
27. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. Husain SR; Puri RK J Neurooncol; 2003 Oct; 65(1):37-48. PubMed ID: 14649884 [TBL] [Abstract][Full Text] [Related]
29. Antiangiogenic activity of endostatin inhibits C6 glioma growth. Peroulis I; Jonas N; Saleh M Int J Cancer; 2002 Feb; 97(6):839-45. PubMed ID: 11857365 [TBL] [Abstract][Full Text] [Related]
30. Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model. Osterberg N; Ferrara N; Vacher J; Gaedicke S; Niedermann G; Weyerbrock A; Doostkam S; Schaefer HE; Plate KH; Machein MR Neuro Oncol; 2016 Jul; 18(7):939-49. PubMed ID: 26951383 [TBL] [Abstract][Full Text] [Related]
31. NDRG1 overexpressing gliomas are characterized by reduced tumor vascularization and resistance to antiangiogenic treatment. Broggini T; Wüstner M; Harms C; Stange L; Blaes J; Thomé C; Harms U; Mueller S; Weiler M; Wick W; Vajkoczy P; Czabanka M Cancer Lett; 2016 Oct; 380(2):568-576. PubMed ID: 26297987 [TBL] [Abstract][Full Text] [Related]
32. REIC/Dkk-3 induces cell death in human malignant glioma. Mizobuchi Y; Matsuzaki K; Kuwayama K; Kitazato K; Mure H; Kageji T; Nagahiro S Neuro Oncol; 2008 Jun; 10(3):244-53. PubMed ID: 18443132 [TBL] [Abstract][Full Text] [Related]
33. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. Scholz A; Harter PN; Cremer S; Yalcin BH; Gurnik S; Yamaji M; Di Tacchio M; Sommer K; Baumgarten P; Bähr O; Steinbach JP; Trojan J; Glas M; Herrlinger U; Krex D; Meinhardt M; Weyerbrock A; Timmer M; Goldbrunner R; Deckert M; Braun C; Schittenhelm J; Frueh JT; Ullrich E; Mittelbronn M; Plate KH; Reiss Y EMBO Mol Med; 2016 Jan; 8(1):39-57. PubMed ID: 26666269 [TBL] [Abstract][Full Text] [Related]
34. Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. Jensen RL; Ragel BT; Whang K; Gillespie D J Neurooncol; 2006 Jul; 78(3):233-47. PubMed ID: 16612574 [TBL] [Abstract][Full Text] [Related]
35. The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model. Veeravagu A; Hou LC; Hsu AR; Cai W; Greve JM; Chen X; Tse V Neurol Res; 2008 Nov; 30(9):952-9. PubMed ID: 18662497 [TBL] [Abstract][Full Text] [Related]
36. Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development. Hong YK; Chung DS; Joe YA; Yang YJ; Kim KM; Park YS; Yung WK; Kang JK Clin Cancer Res; 2000 Aug; 6(8):3354-60. PubMed ID: 10955823 [TBL] [Abstract][Full Text] [Related]
37. Brain gliomas and growth factors: immunohistochemical, immunofluorescence, flow cytometry and RT-PCR profile in pediatric age. Taurone S; Spoletini M; Chiappetta C; Di Gioia C; Carletti R; Greco A; Agostinelli E; Ralli M; Giangaspero F; Artico M; Pastore FS; Scarpa S; Gobbi P; Di Liddo R J Biol Regul Homeost Agents; 2019 September-October,; 33(5):1451-1463. PubMed ID: 31507151 [TBL] [Abstract][Full Text] [Related]
38. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators. Wu J; Jordan M; Waxman DJ BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027 [TBL] [Abstract][Full Text] [Related]
39. Cereport (RMP-7) increases carboplatin levels in brain tumors after pretreatment with dexamethasone. Dean RL; Emerich DF; Hasler BP; Bartus RT Neuro Oncol; 1999 Oct; 1(4):268-74. PubMed ID: 11550318 [TBL] [Abstract][Full Text] [Related]
40. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor. Shibuya M FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]